BET-BAY 002 is a potent BET inhibitor; shows efficacy in a multiple myeloma model.

BET inhibitor CF53 is a highly potent, orally active inhibitor of bromodomain and extra-terminal (BET) with Ki of <1 nM (BRD4 BD1).

BAZ2-ICR is a selective BAZ2 bromodomain inhibitor (Kd values are 109 and 170 nM for BAZ2A and BAZ2B respectively).

ACY-957 (ACY957) is a potent, selective inhibitor of HDAC1 and HDAC2 with IC50 of 7 and 18 nM, shows limited activity against HDAC3 (IC50=1,300 nM) and no activity against HDAC4/5/6/7/8/9 (IC50>20 nM).

A potent, selective. covalent protein lysine methyltransferase SETD8 inhibitor with IC50 of 804 nM.

A potent, selective HDAC1 inhibitor with IC50 of 1.5 uM.

A potent, selective and cell active lysine methyltransferase SMYD2 inhibitor with IC50 of 2.8 nM.

A potent BET bromodomian inhibitor with IC50 of 3-7 nM for BRD2/3/4 BD1 and BD2..

A potent and selective HDAC8 inhibitor with IC50 of 70 nM.

A potent and selective HDAC8 inhibitor with IC50 of 0.5 uM..

A novel SAM-competitive, highly selective, orally bioavailable EZH1/2 dual inhibitor with IC50 of 16/50 nM, respectively.

A novel potent, selective, orally active CBP/p300 bromodomain with IC50 of 1.0 nM.

A novel potent, selective Sirt2 inhibitor with IC50 of 3.745 uM.

A novel potent, selective Sirt2 inhibitor with IC50 of 0.118 uM.

A novel potent, selective and reversible dual inhibitor of G9a/DNMTs with IC50 of 16 nM and 32 nM for G9a and DNMT1, respectively.

A novel potent specific histone acetyltransferaseTip60 inhibitor.

A novel potent specific histone acetyltransferaseTip60 inhibitor.

A novel bromodomain BRD4 inhibitor that significantly induces HIV-1 reactivation.

A novel a potent, selective inhibitor of BRD4 with Kd of 550 nM, cellular IC50 of 724 nM.

A new compound which is similar with +JQ-1，BET bromodomain inhibitor

A first-in-class, dual inhibitor of PDE5 and HDAC that inhibits HDAC1/2/3/6 (IC50=310/490/322/91 nM, respectively) and PDE5 (IC50=60 nM).

A first-in-class, dual inhibitor of PDE5 and HDAC that inhibits HDAC1/2/3/6 (IC50=310/490/322/91 nM, respectively) and PDE5 (IC50=60 nM).

A first-in-class, dual inhibitor of PDE5 and HDAC that inhibits HDAC1/2/3/6 (IC50=310/490/322/91 nM, respectively) and PDE5 (IC50=60 nM).

A cell permeable CBP bromodomain inhibitor with Kd of 19 uM.

A cell permeable CBP bromodomain inhibitor with Kd of 19 uM.

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

>98%,Standard References